The Quantellect read.As of Nov 19, 2026, 5 active firms cover Whitehawk Therapeutics, Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $7.00 to $10.00, a moderate spread. The average target of $8.60 sits 174% above the current $3.13. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-1.00 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.60
+174.3% upside
Average target across 5 active firms as of Nov 19, 2026 vs $3.14 current
Highest Target$10.00
Average Target$8.60
Lowest Target$7.00
Detailed analyst forecasts for WHWK
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate WHWK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
WHWK EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.24 – $-0.22 · 2 analysts · -28% YoY
Next period, 2 analysts expect Whitehawk Therapeutics, Inc. to earn $-0.23 a share (range $-0.24 – $-0.22), versus $-0.32 a year earlier. Full-year consensus is $-0.97, growing to $-1.00 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Whitehawk Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on WHWK.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Neutral
No targeton WHWK
Overall win rate
42%
+ Follow
#2
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$8.00+155.2% to target
Overall win rate
29%
+ Follow
#3
Jonathan Chang
Leerink Partners
Buy
$9.00+187.1% to target
Coverage
—
+ Follow
#4
YZ
Yuan Zhi
B. Riley Securities
Buy
$10.00+219.0% to target
Coverage
—
+ Follow
#5
DA
Dara Azar
Stifel Nicolaus
Buy
$9.00+187.1% to target
Coverage
—
+ Follow
WHWK stock forecast FAQ
What is WHWK's average 12-month price target?+
The 5 active firms with a live target average $8.60 for Whitehawk Therapeutics, Inc. over the next 12 months, ranging from a $10.00 high to a $7.00 low, as of Nov 19, 2026.
Is WHWK stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for WHWK?+
The Street-high target is $10.00 (B. Riley Securities), and the Street-low is $7.00 (Jones Trading). The average of all 5 active-firm targets is $8.60.
How many active Wall Street firms cover WHWK?+
5 active firms have a recognized rating on Whitehawk Therapeutics, Inc. as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering WHWK?+
Among analysts who currently cover WHWK, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #215). Their current call is Neutral.
What is Whitehawk Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.24 – $-0.22) across 2 analysts. Full-year EPS is projected at $-0.97, rising to $-1.00 the following year.
How much revenue is Whitehawk Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading WHWK lately?+
As of Nov 19, 2026, 5 of 5 active firms rate WHWK a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their WHWK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.